This company listing is no longer active
ASLAN Pharmaceuticals 과거 수익 실적
과거 기준 확인 0/6
ASLAN Pharmaceuticals's earnings have been declining at an average annual rate of -6.5%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been growing at an average rate of 55.7% per year.
주요 정보
-6.5%
수익 성장률
18.3%
EPS 성장률
| Biotechs 산업 성장 | 17.0% |
| 매출 성장률 | 55.7% |
| 자기자본 수익률 | n/a |
| 순이익 | -291.9% |
| 최근 수익 업데이트 | 31 Mar 2024 |
수익 및 비용 분석
ASLAN Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 31 Mar 24 | 12 | -35 | 13 | 34 |
| 31 Dec 23 | 12 | -44 | 13 | 42 |
| 30 Sep 23 | 12 | -45 | 13 | 44 |
| 30 Jun 23 | 12 | -46 | 12 | 44 |
| 31 Mar 23 | 0 | -58 | 11 | 43 |
| 31 Dec 22 | 0 | -51 | 10 | 38 |
| 30 Sep 22 | 0 | -46 | 9 | 36 |
| 30 Jun 22 | 0 | -45 | 10 | 34 |
| 31 Mar 22 | 0 | -38 | 11 | 28 |
| 31 Dec 21 | 0 | -31 | 12 | 22 |
| 30 Sep 21 | 0 | -28 | 13 | 16 |
| 30 Jun 21 | 0 | -21 | 11 | 13 |
| 31 Mar 21 | 0 | -20 | 9 | 11 |
| 31 Dec 20 | 0 | -16 | 7 | 9 |
| 30 Sep 20 | 0 | -40 | 7 | 9 |
| 30 Jun 20 | 0 | -41 | 7 | 11 |
| 31 Mar 20 | 0 | -47 | 7 | 15 |
| 31 Dec 19 | 3 | -47 | 9 | 17 |
| 30 Sep 19 | 3 | -27 | 7 | 22 |
| 30 Jun 19 | 3 | -34 | 9 | 27 |
| 31 Mar 19 | 3 | -37 | 10 | 30 |
| 31 Dec 18 | 0 | -42 | 11 | 32 |
| 30 Sep 18 | 0 | -45 | 11 | 34 |
| 30 Jun 18 | 0 | -41 | 11 | 31 |
| 31 Mar 18 | 0 | -42 | 10 | 31 |
| 31 Dec 17 | 0 | -41 | 9 | 31 |
| 30 Sep 17 | 1 | -33 | 9 | 25 |
| 30 Jun 17 | 12 | -19 | 8 | 22 |
| 31 Mar 17 | 12 | -14 | 8 | 18 |
| 31 Dec 16 | 11 | -9 | 7 | 13 |
| 30 Sep 16 | 11 | -7 | 8 | 8 |
| 30 Jun 16 | 0 | -15 | 7 | 7 |
| 31 Mar 16 | 0 | -15 | 7 | 7 |
| 31 Dec 15 | 0 | -14 | 7 | 6 |
양질의 수익: ASLN is currently unprofitable.
이익 마진 증가: ASLN is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: ASLN is unprofitable, and losses have increased over the past 5 years at a rate of 6.5% per year.
성장 가속화: Unable to compare ASLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: ASLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
자기자본 수익률
높은 ROE: ASLN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.